You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

Biogen Idec seeks FDA OK for new MS drug

Biogen Idec Inc., which cemented its place as the dominant multiple sclerosis drug maker in March when it won US approval to sell an MS pill, said Tuesday it has applied to the Food and Drug Administration to market a third injectable MS drug.

The drug, called Plegridy, is a new version of the Weston biotechnology company’s first — and hugely successful — MS treatment, Avonex. While both drugs have the same active ingredient, interferon beta, Biogen Idec has attached a polymer called polyethylene glycol, or peg, to Plegridy that increases the exposure of the drug, allowing patients to take doses less frequently.

Loading comments...

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week